Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ANI Pharmaceuticals stock | $30.57

Own ANI Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

ANI Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. ANI Pharmaceuticals shares (ANIP) are listed on the NASDAQ and all prices are listed in US Dollars. ANI Pharmaceuticals employs 338 staff and has a trailing 12-month revenue of around USD$199.2 million.

How to buy shares in ANI Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ANI Pharmaceuticals. Find the stock by name or ticker symbol: ANIP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ANI Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$30.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ANI Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ANI Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ANI Pharmaceuticals share price

Use our graph to track the performance of ANIP stocks over time.

ANI Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$30.57
52-week rangeUSD$23.55 - USD$68.19
50-day moving average USD$28.8021
200-day moving average USD$29.4699
Wall St. target priceUSD$38.33
PE ratio 77.58
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.337

Buy ANI Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ANI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ANI Pharmaceuticals price performance over time

Historical closes compared with the close of $30.57 from 2020-12-09

1 week (2021-01-08) -2.36%
1 month (2020-12-16) -0.62%
3 months (2020-10-15) 4.66%
6 months (2020-07-15) 3.42%
1 year (2020-01-15) -48.66%
2 years (2019-01-15) -42.51%
3 years (2018-01-12) 72.3
5 years (2016-01-15) 35.67

Is ANI Pharmaceuticals under- or over-valued?

Valuing ANI Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ANI Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ANI Pharmaceuticals's P/E ratio

ANI Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, ANI Pharmaceuticals shares trade at around 78x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ANI Pharmaceuticals's PEG ratio

ANI Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ANI Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ANI Pharmaceuticals's EBITDA

ANI Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.1 million.

The EBITDA is a measure of a ANI Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

ANI Pharmaceuticals financials

Revenue TTM USD$199.2 million
Gross profit TTM USD$143.4 million
Return on assets TTM -3.16%
Return on equity TTM -11.64%
Profit margin -11.92%
Book value $16.264
Market capitalisation USD$346 million

TTM: trailing 12 months

Shorting ANI Pharmaceuticals shares

There are currently 613,024 ANI Pharmaceuticals shares held short by investors – that's known as ANI Pharmaceuticals's "short interest". This figure is 2.1% up from 600,659 last month.

There are a few different ways that this level of interest in shorting ANI Pharmaceuticals shares can be evaluated.

ANI Pharmaceuticals's "short interest ratio" (SIR)

ANI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ANI Pharmaceuticals shares currently shorted divided by the average quantity of ANI Pharmaceuticals shares traded daily (recently around 59924.144672532). ANI Pharmaceuticals's SIR currently stands at 10.23. In other words for every 100,000 ANI Pharmaceuticals shares traded daily on the market, roughly 10230 shares are currently held short.

However ANI Pharmaceuticals's short interest can also be evaluated against the total number of ANI Pharmaceuticals shares, or, against the total number of tradable ANI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ANI Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 ANI Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable ANI Pharmaceuticals shares, roughly 75 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ANI Pharmaceuticals.

Find out more about how you can short ANI Pharmaceuticals stock.

ANI Pharmaceuticals share dividends

We're not expecting ANI Pharmaceuticals to pay a dividend over the next 12 months.

Have ANI Pharmaceuticals's shares ever split?

ANI Pharmaceuticals's shares were split on a 1:6 basis on 18 July 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ANI Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for ANI Pharmaceuticals shares which in turn could have impacted ANI Pharmaceuticals's share price.

ANI Pharmaceuticals share price volatility

Over the last 12 months, ANI Pharmaceuticals's shares have ranged in value from as little as $23.55 up to $68.19. A popular way to gauge a stock's volatility is its "beta".

ANIP.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ANI Pharmaceuticals's is 1.3391. This would suggest that ANI Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ANI Pharmaceuticals overview

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site